Long-term outcome after en bloc resection of non-small-cell lung cancer invading the pulmonary sulcus and spine

J Thorac Oncol. 2013 Dec;8(12):1538-44. doi: 10.1097/01.JTO.0000437419.31348.a4.

Abstract

Introduction: Lung cancer invading the spine historically has been considered unresectable. Nevertheless, considerable surgical progress has been made since the 1990s potentially allowing for curative resection. Here, we describe our surgical experience and long-term results.

Methods: All patients who underwent en bloc resection of non-small-cell lung cancer invading the pulmonary sulcus and spine between 1991 and 2012 were retrospectively reviewed.

Results: Forty-eight patients were included. Induction therapy consisted mostly of two cycles of cisplatin-etoposide and 45 Gy of concurrent radiation. All tumors were resected en bloc, including the lung, spine, and chest wall. Total vertebrectomy, hemivertebrectomy, and partial vertebrectomy were required in 10 patients (21%), 31 patients (64%), and seven patients (15%), respectively. Complete resection was achieved in 42 patients (88%). Postoperatively, 18 patients (38%) stayed in the intensive care unit for a median of 15 (1-140) days. Thirty-day and in-hospital mortality was 6%. Pathologic response to induction treatment was complete (n = 18) or near complete (n = 6) in 24 patients (50%). After a median follow-up of 26 (0-151) months, 24 patients are alive without recurrence. Overall 5-year survival was 61%. Response to induction therapy (complete/near complete versus other, p = 0.012), resection margin (R0 versus R1/R2, p = 0.009), and length of intensive care unit stay (p = 0.003) were significant prognostic factors in univariate analysis. Response to induction was maintained as prognostic factor in multivariable analysis (p = 0.048).

Conclusions: En bloc resection of the lung, chest wall, and spine for non-small-cell lung cancer invading the pulmonary sulcus and spine is feasible in experienced centers with excellent long-term outcome after careful patient selection. Response to induction was an independent significant prognostic factor.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / mortality
  • Adenocarcinoma / pathology
  • Adenocarcinoma / surgery*
  • Adenocarcinoma / therapy
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Large Cell / mortality
  • Carcinoma, Large Cell / pathology
  • Carcinoma, Large Cell / surgery*
  • Carcinoma, Large Cell / therapy
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / surgery*
  • Carcinoma, Non-Small-Cell Lung / therapy
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / surgery*
  • Carcinoma, Squamous Cell / therapy
  • Chemoradiotherapy, Adjuvant
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology
  • Lung Neoplasms / surgery*
  • Lung Neoplasms / therapy
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Pancoast Syndrome / mortality
  • Pancoast Syndrome / pathology
  • Pancoast Syndrome / surgery*
  • Pancoast Syndrome / therapy
  • Pneumonectomy
  • Prognosis
  • Retrospective Studies
  • Spinal Neoplasms / mortality
  • Spinal Neoplasms / pathology
  • Spinal Neoplasms / surgery*
  • Spinal Neoplasms / therapy
  • Survival Rate